Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 5% status confers therapeutic sensitivity to Atezolizumab in patients with Bladder Urothelial Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression >= 5%.